Inadvertent Disclosure of Oveporexton (TAK-861) Abstract

SEC Filing 6-K (0001395064-25-000122)

Takeda Pharmaceutical Company Limited reported an inadvertent disclosure of an abstract related to their Phase 3 TAK-861-3002 study of oveporexton (TAK-861) for narcolepsy type 1. The abstract, which was slated for presentation at the World Sleep 2025 congress, was mistakenly published on the World Sleep Congress website. Takeda promptly contacted the congress, and the abstract was removed. The company emphasized that this abstract is one of several from their Phase 3 studies and reiterated that the study met all primary and secondary endpoints at week 12. Takeda does not anticipate any significant impact on its consolidated financial results due to this incident. The abstract, which detailed the efficacy and safety of oveporexton, was attached to the filing for transparency.